Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Informing Choice for Neurotechnological Innovation in Pediatric Epilepsy Surgery
EF 2017-18
Résumé
Technological advances have resulted in the adoption of minimally-invasive therapies in pediatric neurosurgery. Unlike novel drug treatments, however, few such innovations are put through the rigours of a randomized control trial. Further, many of these therapies are tested on adult patients first, with unclear evidence as to whether results are generalizable to children. This is of chief concern in the context of pediatric epilepsy, a disorder that affects up to 1% of Canadian children. 30% of children with epilepsy continue to have seizures while on anti-seizure medication, a condition known as drug resistant epilepsy (DRE). Properly selected, up to 70% of DRE patients become seizure-free after surgery. Successful surgery results in long-term improvements in behaviour, emotion, psychosocial interactions, and health-related quality of life. Nevertheless, epilepsy surgery carries with it the risk of infection, damage to adjacent areas of the brain, memory impairment, stroke, hemorrhage and death, as well as a relatively prolonged hospital stay and post-hospital recovery phase. As a result, less invasive interventions have been developed, such as MRI-guided laser interstitial thermal therapy, robot-assisted stereo-EEG, stereotactic radiosurgery, vagal nerve stimulation, and responsive neurostimulation. Decision-making about novel neurotechnologies is often made in the context of inadequate evidence regarding efficacy, safety and long-term side effects. The ethical imperative here is to determine factors in decision-making among Canadian families and physicians when evaluating whether to use a novel neurotechnology for DRE, and to deliver practical decision-making tools that reduce the burden of related choices.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386326
Name
Courchesne Caitlin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Informing Choice for Neurotechnological Innovation in Pediatric Epilepsy Surgery
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Decision-Making; Discrete Choice Experiment (Dce); Epilepsy; Ethics; Health Economics; Neuroethics; Neurosurgery; Neurotechnology; Pediatrics; Qualitative Research
Abstract
Technological advances have resulted in the adoption of minimally-invasive therapies in pediatric neurosurgery. Unlike novel drug treatments, however, few such innovations are put through the rigours of a randomized control trial. Further, many of these therapies are tested on adult patients first, with unclear evidence as to whether results are generalizable to children. This is of chief concern in the context of pediatric epilepsy, a disorder that affects up to 1% of Canadian children. 30% of children with epilepsy continue to have seizures while on anti-seizure medication, a condition known as drug resistant epilepsy (DRE). Properly selected, up to 70% of DRE patients become seizure-free after surgery. Successful surgery results in long-term improvements in behaviour, emotion, psychosocial interactions, and health-related quality of life. Nevertheless, epilepsy surgery carries with it the risk of infection, damage to adjacent areas of the brain, memory impairment, stroke, hemorrhage and death, as well as a relatively prolonged hospital stay and post-hospital recovery phase. As a result, less invasive interventions have been developed, such as MRI-guided laser interstitial thermal therapy, robot-assisted stereo-EEG, stereotactic radiosurgery, vagal nerve stimulation, and responsive neurostimulation. Decision-making about novel neurotechnologies is often made in the context of inadequate evidence regarding efficacy, safety and long-term side effects. The ethical imperative here is to determine factors in decision-making among Canadian families and physicians when evaluating whether to use a novel neurotechnology for DRE, and to deliver practical decision-making tools that reduce the burden of related choices.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Courchesne, Caitlin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~